Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
135 studies found for:    mozobil
Show Display Options
Rank Status Study
1 Completed
Has Results
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
Condition: Healthy
Intervention: Drug: AMD 3100 (Mozobil plerixafor)
2 Completed
Has Results
Alteration in Timing of Plerixafor Administration
Condition: Autologous Transplantation
Intervention: Drug: Plerixafor
3 Completed Mozobil for Autologous Stem Cell Mobilization
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Stem Cell Mobilization;   Autologous Stem Cell Transplantation
Intervention: Drug: Plerixafor
4 Completed Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Mozobil
5 Completed Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection
Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor (mozobil)
6 Completed Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers
Condition: Blood Stem Cell Harvest Failure
Intervention: Drug: Plerixafor
7 Unknown  Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Conditions: Multiple Myeloma;   Non-Hodgkins Lymphoma
Intervention: Drug: Plerixafor
8 Terminated AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
Conditions: Pediatric Acute Myeloblastic Leukemia, Relapsed;   Pediatric Acute Lymphoblastic Leukemia, Relapsed
Intervention: Drug: AMD3100
9 Completed
Has Results
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
Condition: Renal Impairment
Intervention: Drug: plerixafor
10 Active, not recruiting POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Conditions: Relapsed/Refractory AML;   Relapsed/Refractory ALL;   Secondary AML/MDS;   Acute Leukemia of Ambiguous Lineage;   AML;   ALL
Intervention: Drug: Plerixafor Dose Escalation
11 Completed Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
Conditions: Multiple Myeloma;   Lymphoma
Interventions: Drug: Plerixafor;   Other: Observation: Nonintervention
12 Active, not recruiting
Has Results
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant
Condition: Failure of Bone Marrow Graft
Intervention: Drug: Plerixafor
13 Completed Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Intervention: Drug: plerixafor
14 Completed
Has Results
AMD 3100 for Treatment of Myelokathexis
Condition: Neutropenia
Intervention: Drug: AMD3100 or plerixafor
15 Unknown  Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease
Condition: End Stage Liver DIsease
Intervention: Drug: Mobilization with G-CSF and Mozobil
16 Completed Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects
Condition: Diabetes
Intervention: Drug: Mozobil
17 Recruiting To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
Conditions: Pancreatic Adenocarcinoma Metastatic;   Ovarian Serous Adenocarcinoma;   Colorectal Cancer Metastatic
Intervention: Drug: Plerixafor
18 Completed
Has Results
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
Condition: Autologous Stem Cell Transplantation
Intervention: Drug: G-CSF plus plerixafor
19 Completed
Has Results
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma
Intervention: Drug: G-CSF Plus Plerixafor
20 Terminated
Has Results
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
Conditions: Multiple Myeloma;   Lymphoma, Non-Hodgkin's
Intervention: Drug: G-CSF plus plerixafor

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.